#None #Vaccine Adjuvants #QS-21 #Treatment Action Group

Urgent Appeal for Vaccine Adjuvants Supply Stability

A critical report released by the Treatment Action Group (TAG) brings attention to the potential risks associated with the supply of essential vaccine adjuvants, specifically QS-21, which is integral to numerous vaccines that combat global health threats such as malaria, tuberculosis, and more. Published recently, the report stresses that without enhanced transparency and security in the supply chain, we may face unprecedented shortages in the upcoming years.

Insights from the Report

The report, titled "From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance", represents a comprehensive analysis of the global supply chains surrounding QS-21 and MPL, two adjuvants used extensively in vaccines. While only six adjuvants have received FDA approval, this analysis highlights significant vulnerabilities in the market structure that could lead to detrimental gaps in vaccine availability.

QS-21, derived from the soapbark tree, known scientifically as Quillaja saponaria, is renowned for its potency as an adjuvant. This particular tree is indigenous to Chile, meaning that it is susceptible to various environmental challenges such as climate change and natural disasters. The growing demand from sectors outside the vaccine industry, including food, cosmetics, and mining, further complicates the outlook on QS-21's supply.

Current Supply Challenges

The report assesses the current state of the QS-21 supply chain, revealing that while it meets existing demand, the margin for error is alarmingly thin. At present, a single entity, Desert King, dominates the market for quillay saponins used in vaccines, rendering the industry vulnerable to disruptions from various unforeseen events, including trade wars, natural catastrophes, or company bankruptcies.

TAG's TB project co-director, Mike Frick, voiced concerns about this oligopolistic scenario, pointing out that relying on a limited number of suppliers could severely hinder access to vaccines. He emphasizes the pressing need for cooperative strategies amongst governments, industry stakeholders, and funders to establish a reliable, sustainable, and affordable supply mechanism for these essential raw materials.

Recommendations for Action

To mitigate the risks associated with vaccine adjuvant supply, TAG recommends the following critical actions:

• - Enhance Transparency: Monitoring the supply chain to identify potential threats or disruptions.
• - Promote Market Competition: Encouraging diversification within the supply chain to prevent monopolistic practices.
• - Invest in Alternative Production Methods: Development of advanced manufacturing processes, such as aeroponics and cell culture, to reduce reliance on natural resources.
• - Support Collaborative Research: Removal of barriers to research related to adjuvant development, fostering a collaborative environment.

Moreover, the report underscores the historical ties of QS-21 with the Indigenous Mapuche people, who have understood the medicinal value of the soapbark tree for centuries. In light of this, it discusses the moral obligations to ensure equitable access and benefit-sharing frameworks that respect traditional knowledge.

Conclusion

This urgent report serves as a wake-up call for all stakeholders involved in global health and vaccine production. The efficacy of vaccines hinges not only on advanced technology and research but also on ensuring the sustainability of their components, particularly adjuvants like QS-21. Failure to act now could lead to adverse effects on public health initiatives worldwide, undermining efforts to eradicate vaccine-preventable diseases. The onus is on governments, industries, and communities to address these issues collaboratively and proactively to secure a healthier future for all.